RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Canagliflozin Reduces HbA1C in Patients with Stage 3 CKD, with the Change Greater in Patients with Higher eGFR
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 11
SP 13
OP 14
DO 10.1177/155989771311009
UL http://mdc.sagepub.com/content/13/11/13.abstract
AB The sodium glucose cotransporter-2 inhibitor canagliflozin reduces HbA1C level in patients with type 2 diabetes mellitus (T2DM) and stage 3 chronic kidney disease (CKD), an effect that is more pronounced with higher levels of estimated glomerular filtration rate (eGFR), according to the results of a pooled analysis. This article presents the results of this pooled analysis of four randomized, double-blind, placebo-controlled Phase 3 trials that compared canagliflozin with placebo in patients with inadequately controlled T2DM and stage 3 CKD.